Cited by 372Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 380 of the 380 references it cites were found in a registry or an index.

Tau-targeting therapies for Alzheimer disease: current status and future directions

Open access

Congdon, Erin E., Ji, Changyi, Tetlow, Amber M., Jiang, Yixiang, Sigurdsson, Einar M.·2023·Nature Reviews Neurology

DOI 10.1038/s41582-023-00883-2PMC PMC10965012

Open this paper in CoChat — free account Open PDF

Abstract

Alzheimer disease (AD) is the most common cause of dementia in older individuals. AD is characterized pathologically by amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the brain, with associated loss of synapses and neurons, which eventually results in dementia. Many of the early attempts to develop treatments for AD focused on Aβ, but a lack of efficacy of these treatments in terms of slowing disease progression led to a change of strategy towards targeting of tau pathology. Given that tau shows a stronger correlation with symptom severity than does Aβ, targeting of tau is more likely to be efficacious once cognitive decline begins. Anti-tau therapies initially focused on post-translational modifications, inhibition of tau aggregation and stabilization of microtubules. However, trials of many potential drugs were discontinued because of toxicity and/or lack of efficacy. Currently, the majority of tau-targeting agents in clinical trials are immunotherapies. In this Review, we provide an update on the results from the initial immunotherapy trials and an overview of new therapeutic candidates that are in clinical development, as well as considering future directions for tau-targeting therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41582-023-00883-2

Cites

380 of 380 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
Masliah, E., Rockenstein, E. M., Mante, M., Crews, L. A., Spencer, B. J., Adame, A., Patrick, C., Trejo, M., Ubhi, K. K., Rohn, T. T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019338 · Cited by 422
Retracted
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA · doi:10.1001/jama.2023.13239 · Cited by 2,932
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
2022 Alzheimer's disease facts and figures
Anonymous (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12638 · Cited by 2,469
Curcumin as “Curecumin”: From kitchen to clinic
Goel, A., Kunnumakkara, A. B., & Aggarwal, B. B. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.016 · Cited by 2,274

Show all 380 references

Research works printed but not linked: 19

Alzforum. Antisense therapy stifles CSF tau in mild Alzheimer’s disease. Alzforum https://www.alzforum.org/news/conference-coverage/antisense-therapy-stifles-csf-tau-mild-alzheimers-disease-0 (2021).
Alzforum. First hit on aggregated tau: antisense oligonucleotide lowers tangles. Alzforum https://www.alzforum.org/news/conference-coverage/first-hit-aggregated-tau-antisense-oligonucleotide-lowers-tangles (2023).
Ryan, J. M. et al. Phase 1 study in healthy volunteers of the O-GlcNAcase inhibitor ASN120290 as a novel therapy for progressive supranuclear palsy and related tauopathies [abstract O1-12-05]. Alzheimers Dement. 14 (7S Part 4), 251 (2018).
Shcherbinin, S. et al. Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme: translation from rat to human: neuroimaging/evaluating treatments. Alzheimers Dement. 16, e040558 (2020).
Alzforum. Tau inhibitor fails again – subgroup analysis irks clinicians at CTAD. Alzforum https://www.alzforum.org/news/conference-coverage/tau-inhibitor-fails-again-subgroup-analysis-irks-clinicians-ctad (2016).
Alzforum. In first phase 3 trial, the Tau drug LMTM did not work. Period. Alzforum http://www.alzforum.org/news/conference-coverage/first-phase-3-trial-tau-drug-lmtm-did-not-work-period#show-more (2016).
Alzforum. First round of FTD therapeutics fell short, but many more are up and running. Alzforum https://www.alzforum.org/news/conference-coverage/first-round-ftd-therapeutics-fell-short-many-more-are-and-running (2016).
Boutajangout, A., Ingadottir, J., Davies, P. & Sigurdsson, E. M. Passive tau immuntherapy diminishes functional decline and clears tau aggregates in a mouse model of tauopathy [abstract P3-427]. Alzheimers Dement. 6 (4S Part 19), S578 (2010).
Alzforum. Active tau vaccine: hints of slowing neurodegeneration. Alzforum https://www.alzforum.org/news/conference-coverage/active-tau-vaccine-hints-slowing-neurodegeneration (2020).
UCB. UCB presents UCB0107 anti-Tau immunotherapy Phase I study Results at World Movement Disorders Conference®. UCB https://www.ucb.com/stories-media/Press-Releases/article/UCB-presents-UCB0107-anti-Tau-immunotherapy-Phase-I-study-results-at-World-Movement-Disorders-Conference (2019).
Alzforum. N-terminal tau antibodies fade, mid-domain ones push to the fore. Alzforum https://www.alzforum.org/news/conference-coverage/n-terminal-tau-antibodies-fade-mid-domain-ones-push-fore (2021).
Alzforum. More tau antibodies bid adieu; semorinemab keeps foot in door. Alzforum https://www.alzforum.org/news/conference-coverage/more-tau-antibodies-bid-adieu-semorinemab-keeps-foot-door (2021).
Eisai. Eisai presents data showing quantification of tau microtubule binding region in cerebrospinal fluid and the identification of a target engagement biomarker for the new anti-tau antibody E2814 at Alzheimer’s Association International Conference (AAIC) 2019. Eisai https://www.eisai.com/news/2019/news201955.html (2019).
Horie, K. et al. Quantification of the tau microtubule binding region (MTBR) in cerebrospinal fluid and subsequent validation of target engagement assay for E2814, a novel anti-tau therapeutic antibody. Alzheimers Dement. 15(7S Part 31), 1598–1599 (2019).
Zhou, J. et al. E2814: an anti-tau therapy engages its CNS target and affects the downstream tangle-specific biomarker MTBR-tau243 in dominantly inherited Alzheimer’s disease [abstract]. Presented at the Alzheimer’s Association International Conference, Amsterdam, Netherlands, and Online 2023 (2023).
Rawal, S. et al. Safety, pharmacokinetics and immunogenicity of single and multiple ascending doses of the anti-tau therapeutic antibody E2814: a phase 1, first-in-human (FIH) study in healthy subjects [abstract P1-909]. Presented at the Alzheimer’s Association International Conference, Amsterdam, Netherlands, and Online (2023).
Galpern, W. R. et al. A single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-phospho-tau antibody JNJ-63733657 in healthy subjects [abstract P1-052]. Alzheimers Dement. 15 (7S Part 5), 252–253 (2019).
Prothena. Prothena reports topline phase 1 single ascending dose study results of PRX005, a novel anti-MTBR-tau antibody for the potential treatment of Alzheimer’s disease. Prothena https://ir.prothena.com/investors/press-releases/news-details/2023/Prothena-Reports-Topline-Phase-1-Single-Ascending-Dose-Study-Results-of-PRX005-a-Novel-Anti-MTBR-Tau-Antibody-for-the-Potential-Treatment-of-Alzheimers-Disease/default.aspx (2023).
Martenyi, F. et al. PRX005, a novel anti-MTBR tau monoclonal antibody: results from a first-in-human double-blind, placebo-controlled, single ascending dose phase 1 study [abstract P1-727]. Presented at the Alzheimer’s Association International Conference, Amsterdam, Netherlands, and Online (2023).

Sorted by citations

Items 101–200 of 372

Overview of Proteomic Analysis of Amyloid Plaques and Neurofibrillary Tangles in Alzheimer’s Disease
Grewal, A., Raikundalia, S., Zaia, J., & Sethi, M. K. (2025) · Biomolecules · doi:10.3390/biom15091310 · Cited by 9
Exploring the role of insulin resistance in bridging the metabolic syndrome and Alzheimer’s disease-a review of mechanistic studies
Wang, S., Shi, Y., Xin, R., Kang, H., Xiong, H., & Ren, J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1614006 · Cited by 12
Recent advances in Alzheimer’s disease: From molecular mechanisms to therapeutic strategies
Rudman, M. D., Ulrich, J. D., & Holtzman, D. M. (2026) · Cell · doi:10.1016/j.cell.2026.06.006 · Cited by 12
Generation of nanobodies with conformational specificity for tau oligomers that recognize tau aggregates from human Alzheimer's disease samples
McArthur, N., Squire, J. D., Onyeachonam, O. J., Bhatt, N. N., Jerez, C., Holberton, A. L., Tessier, P. M., Wood, L. B., Kayed, R., & Kane, R. S. (2024) · Biomaterials Science · doi:10.1039/d4bm00707g · Cited by 8
Essential tremor with tau pathology features seeds indistinguishable in conformation from Alzheimer’s disease and primary age-related tauopathy
Saez-Calveras, N., Vaquer‐Alicea, J., White, C. L., Tak, Y., Cosentino, S., Faust, P. L., Louis, E. D., & Diamond, M. I. (2025) · Acta Neuropathologica · doi:10.1007/s00401-024-02843-6 · Cited by 9
Selection of lansoprazole from an FDA-approved drug library to inhibit the Alzheimer’s disease seed-dependent formation of tau aggregates
Ahmed, I., Shimonaka, S., Uddin, M. N., Elahi, M., Ishiguro, K., Hasegawa, M., Hattori, N., & Motoi, Y. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1368291 · Cited by 8
Optogenetics to biomolecular phase separation in neurodegenerative diseases
Park, K. H., & Kim, K. W. (2025) · Molecules and Cells · doi:10.1016/j.mocell.2025.100247 · Cited by 8
Clearing truncated tau protein restores neuronal function and prevents microglia activation in tauopathy mice
Martín‐Ávila, A., Modak, S., Rajamohamedsait, H. B., Dodge, A., Shamir, D. B., Krishnaswamy, S., Sandusky‐Beltran, L. A., Walker, M., Lin, Y., Congdon, E. E., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116291 · Cited by 7
Advances of therapeutic strategies for Alzheimer’s disease
Guo, X., Yue, R.-Z., Cui, Z., Wang, S., Jia, T., Li, W., Zhang, W., Shan, L., & Li, C. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13456-8 · Cited by 9
Tau post-translational modifications in Alzheimer's disease: Insights into pathogenesis, therapeutic strategies, and diagnostic advances
Lei, H., Chen, X., Ruan, L., Liu, X., Ye, F., Li, K., Cheng, W., Yu, B., Di, C., & Di, C. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102927 · Cited by 7
Beyond Conventional Pharmacotherapy: Unraveling Mechanisms and Advancing Multi-Target Strategies in Alzheimer’s Disease
Stanciu, G. D. (2025) · Pharmaceuticals · doi:10.3390/ph18121797 · Cited by 7
Tau protein: Physiological functions and multifaceted roles in neurodegenerative and psychiatric disorders
Tang, F., Wei, J., Wong, M.-L., & Lei, P. (2025) · Genomic psychiatry : · doi:10.61373/gp025i.0122 · Cited by 7
Combination of Tramiprosate, Curcumin, and SP600125 Reduces the Neuropathological Phenotype in Familial Alzheimer Disease PSEN1 I416T Cholinergic-like Neurons
Gomez-Sequeda, N., Jiménez-Del-Río, M., & Velez‐Pardo, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094925 · Cited by 7
Traditional Chinese medicine in Alzheimer's disease: From the perspective of GSK-3β and Tau hyperphosphorylation
Wang, M., Huang, W., Huang, J., Shi, J., Huang, N., & Luo, Y. (2024) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2024.100543 · Cited by 9
Uncovering the epigenetic regulatory clues of PRRT1 in Alzheimer’s disease: a strategy integrating multi-omics analysis with explainable machine learning
Wang, F., Liang, Y., & Wang, Q. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01646-x · Cited by 7
Intraneuronal Aβ accumulation causes tau hyperphosphorylation via endolysosomal leakage
Gao, Y., Wang, L., Doeswijk, T., Winblad, B. G., Schedin‐Weiss, S., & Tjernberg, L. O. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70091 · Cited by 8
Voluntary wheel running decreases amyloidogenic pathway and rescues cognition and mitochondrial energy metabolism in middle-aged female 3xTg-AD mouse model of Alzheimer's disease
dos Santos, J. R., Catalão, C. H. R., Vulczak, A., Azzolini, A. E. C. S., & Alberici, L. C. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241289388 · Cited by 6
Harnessing network pharmacology and in silico drug discovery to uncover new targets and therapeutics for Alzheimer's disease
Al‐Madhagi, H., & Nassar, H. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.109781 · Cited by 6
Ginsenoside 1 mitigates postoperative cognitive dysfunction by enhancing microglial Aβ clearance through the endo-lysosomal pathway
Xu, J., Zhao, Y., Wang, G., & Tian, W. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114281 · Cited by 7
Gut microbiota and serum metabolomics unveil the role of Phellinus ribis polysaccharides in improving Alzheimer's disease symptoms in senescence-accelerated mice
Zhang, Z., Wang, S., Rong, R., Zhang, G., Li, Z., Li, Y., Wang, R., Liu, Y., & Li, K. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01632-8 · Cited by 6
Management of Alzheimer's Disease With Nanotechnological Interventions and Novel Therapeutics
Shahrukh, M., Ahmad, S., Zaafar, M., Hasan, N., & Ahmad, F. J. (2025) · Drug Development Research · doi:10.1002/ddr.70120 · Cited by 8
Unraveling the Mechanisms of Active Saponins from Rhizoma Anemarrhenae Against Ferroptosis in Alzheimer’s Disease: Integrating Network Pharmacology, Cell Membrane Chromatography, and Experimental Validation
Peng, J., Lu, Z., Sai, F., Liang, M., Zhang, X., Ru, D., Song, Y., Wei, X., Gao, L., & Wang, H.-Q. (2025) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x25500429 · Cited by 7
Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors
Benetik, S. F., Proj, M., Knez, D., Košak, U., Meden, A., Krajšek, K., Pišlar, A. H., Horvat, S., Švajger, U., Tešić, N., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00933 · Cited by 6
Roles and therapeutic potential of PARP-1 in neurodegenerative diseases
Liu, C., Lai, F., Zhang, T., Mao, K., Wan, H., & He, Y. T. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117373 · Cited by 7
Advancement of disease-modifying therapy of Alzheimer’s disease: from the perspective of new revised criteria for diagnosis and staging of Alzheimer’s disease
Wu, J., Geng, C., Liu, L., & Tang, Y. (2025) · Medicine Plus · doi:10.1016/j.medp.2025.100112 · Cited by 8
Molecular insights into curcumin’s Anti-Alzheimer’s potential through Amyloid-β and Tau interactions
Reddy, K. G., Swain, S., Aryan, A., & Metya, A. K. (2025) · Discover Molecules · doi:10.1007/s44345-025-00038-4 · Cited by 6
Electrophysiological insights into Alzheimer's disease: A review of human and animal studies
Calvin, K., McNeela, A. M., Osse, A. M. L., Bhasin, G., Ridenour, M., Kinney, J. W., & Hyman, J. M. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105987 · Cited by 8
Association of objective subtle cognitive difficulties with amyloid-β and tau deposition compared to subjective cognitive decline
Mao, X., Li, A., Wang, Y., Wang, Y., Ren, S., He, K., Guan, Y., Huang, Q., Guo, Q., Li, Z., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07080-x · Cited by 6
Integrative network analysis reveals novel moderators of Aβ-Tau interaction in Alzheimer's disease
Kitani, A., Matsui, Y., & Initiative, F. T. A. D. N. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-025-01705-x · Cited by 6
Rational Modulation of Liquid–Liquid Phase Separation Offers Novel Ways to Combat Tauopathies
Zhang, X., Wang, L., Lin, N., Gao, M. Y., & Huang, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146709 · Cited by 7
Alzheimer’s disease: Clinical trials to watch
Sabbagh, M. N., Kennedy, J. L., Majeed, J., & Decourt, B. (2025) · Med · doi:10.1016/j.medj.2025.100771 · Cited by 5
Eleusenticosides A–O: Neuroprotective Triterpenoid Saponins from the Leaves of Eleutherococcus senticosus Using a Building-Block-Based Molecular Networking Strategy
Zhou, Y., Li, X., Chen, P.-P., Luo, W.-J., Ren, Y., Zhou, J., Li, H., Huang, Y.-H., Wu, Y., Piao, X., et al. (2025) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5c00763 · Cited by 5
Neuroprotective synergy of curcumin and Glycyrrhiza glabra in an alzheimer’s model: implications for inflammation and redox pathways
Liu, S., Yan, J., & Dong, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1661706 · Cited by 6
Oral Exposure to Food‐Grade Nanoparticles Poses a Risk of Alzheimer's Disease‐Like Symptoms by Triggering Autophagy Defects in Neurons
Shang, J., Yan, J., Lou, H., Jiang, X., Wang, Z., Gao, Y., Fan, X., & Lu, X. (2025) · Advanced Science · doi:10.1002/advs.202508096 · Cited by 6
Targeting Amyloid-β Proteins as Potential Alzheimer’s Disease Therapeutics: Anti-Amyloid Drug Discovery, Emerging Therapeutics, Clinical Trials and Implications for Public Health
Abduljawad, A. A., Alkinani, K. B., Zaakan, A., AlGhamdi, A. S., Hamdoon, A. A. E., Alshanbari, B. H., Alshehri, A. A., Alluhaybi, B. B., Alqashi, S. O. I., & Abduljawad, R. A. (2025) · Pharmaceuticals · doi:10.3390/ph18111731 · Cited by 7
A machine learning–enabled blood transcriptomic signature for digital diagnosis and subtyping of Alzheimer’s disease
Ma, S., Chen, D., Li, Y., Liu, Y., Zhou, M., Wang, J., Yao, Y., Chen, Y., & Wu, G. (2026) · npj Digital Medicine · doi:10.1038/s41746-025-02305-7 · Cited by 8
Advances in Alzheimer’s disease: mechanistic insights and therapeutic targets
Jia, Y.-J., Ge, Y., Li, B., Yang, Y., Chen, H., Liu, J., Guo, J., Yu, J., Ye, K., Wang, J., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-2991-7 · Cited by 6
Tau Protein Aggregation Inhibitors—Therapeutic Strategy for Concurrent Tau and Amyloid Aggregation Inhibition
Schreiner, T. G., Ciobanu, R. C., & Schreiner, O. D. (2026) · Biomedicines · doi:10.3390/biomedicines14030522 · Cited by 6
Ceperognastat in Early Symptomatic Alzheimer Disease
Fleisher, A., Munsie, L. M., Mancini, M., Cheng, Y., Guo, J., Nuthall, H. N., Svaldi, D. O., Kotari, V., Kielbasa, W., Hutton, M. L., et al. (2026) · JAMA · doi:10.1001/jama.2026.12768 · Cited by 6
Exploring Tau Fibril-Disaggregating and Antioxidating Molecules Binding to Membrane-Bound Amyloid Oligomers Using Machine Learning-Enhanced Docking and Molecular Dynamics
Segura, L., Santos, N., Flores, R., Sikazwe, D., McGibbon, M., Blay, V., & Cheng, K. H. (2024) · Molecules · doi:10.3390/molecules29122818 · Cited by 5
Delivery of Neuroregenerative Proteins to the Brain for Treatments of Neurodegenerative Brain Diseases
Ebert, E. T., Schwinghamer, K., & Siahaan, T. J. (2024) · Life · doi:10.3390/life14111456 · Cited by 7
Tau in Multiple Sclerosis: A Review of Therapeutic Potential
Hoehne, C. L., Stüve, O., & Stopschinski, B. E. (2025) · Current Treatment Options in Neurology · doi:10.1007/s11940-024-00820-8 · Cited by 6
Hiding in plain sight: Do recruited dendritic cells surround amyloid plaques in Alzheimer’s disease?
Nelson, R. B., Rose, K. N., Menniti, F. S., & Zorn, S. H. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116258 · Cited by 5
The Current Role of Tau PET Imaging in Neurodegeneration
Vanderlinden, G., Vandenberghe, R. R., Vandenbulcke, M., & Laere, K. V. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.03.002 · Cited by 7
Pharmacological Blocking of Adiponectin Receptors Induces Alzheimer’s Disease-like Neuropathology and Impairs Hippocampal Function
Guo, H., Ou, H., Yu, J., Yau, S., & Tsang, H. W. H. (2025) · Biomedicines · doi:10.3390/biomedicines13051056 · Cited by 5
Immunotherapy in Alzheimer's Disease: From the Bench to the Bedside
Diniz, B. S. (2024) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2024.01.013 · Cited by 5
Neurons accumulate disease-specific somatic genomic changes across tau pathologic states in Alzheimer’s diseasePreprint
Jin, B., Brown, K. S.-M., Smirnov, D. S., Naik, S. M., Kirkham, S. L., Hennessey, E. L., Dong, G., Mao, S., Wijethunga, S. P., Connors, T. R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.26.656152 · Cited by 6
Differential roles of human tau isoforms in the modulation of inflammation and development of neuropathology
Spencer, B. J., Schueler, A., Sung, D., & Rissman, R. A. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106942 · Cited by 4
PI31 expression is neuroprotective in a mouse model of early-onset parkinsonism
Rodríguez, J. A. R., Minis, A., Aref, R., Nguyen, H. H. M., Sun, F., & Steller, H. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2511899122 · Cited by 4
Sorafenib promotes the E3 ubiquitin ligase FBXW7 to increase tau degradation and ameliorate tauopathies
Zhou, Y., Wang, Y., Yang, H., Zhang, C., Meng, J., Zhang, L., Li, K., Huang, L.-L., Zhang, X., Luo, H., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.09.024 · Cited by 5
Design and application of a Tau seed amplification assay for screening inhibitors of Tau seeding
Gorski, D., Evans, H., Allison, T., Barria, C., Harrison, D., Banerjee, V., Méndez, N., Shahnawaz, M., Kaalund, S. S., Folke, J., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01855-y · Cited by 5
Axonal tau reduction ameliorates tau and amyloid pathology in a mouse model of Alzheimer’s disease
Zare, A., Salehi, S., Bader, J. M., Wiessler, A.-L., Prokesch, M., Albrecht, V., Villmann, C., Mann, M., Briese, M., & Sendtner, M. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00499-0 · Cited by 4
Human induced pluripotent stem cell models for Alzheimer’s disease research: a bibliometric analysis
Sun, Y., Liu, Z., Zhang, Z., Kang, Y., Wang, X., Zhang, Y., Liu, Y., & Zhao, P. (2025) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2025.1548701 · Cited by 4
Large-scale seroepidemiology uncovers nephro-urological pathologies in persons with tau autoimmunityPreprint
Magalhães, A. D., Emmenegger, M., Cecco, E. D., Carta, M. C., Frontzek, K., Chincisan, A., Guo, J., Hornemann, S., & Aguzzi, A. (2021) · medRxiv · doi:10.1101/2021.11.24.21266833 · Cited by 4
Visualization Analysis of Tau Protein in the Brain of Alzheimer’s Disease: A Scoping Literature Review
Zhang, D.-Q., Yang, X., Niu, H.-B., Sun, X.-C., Cao, D., Li, A., Yue, J., Li, X.-L., & Zhang, Q. (2025) · Current Alzheimer Research · doi:10.2174/0115672050351995241223065923 · Cited by 3
Acute targeting of N-terminal tau protein has long-lasting beneficial effects in Tg2576 APP/Aβ mouse model by reducing cognitive impairment, cerebral Aβ-amyloidosis, synaptic remodeling and microgliosis later in life
Latina, V., Introna, M. D., Malerba, F., Florio, R., Balzamino, B. O., Natale, G. D., Sciacca, M. F. M., Pappalardo, G., Micera, A., Pignataro, A., et al. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02022-y · Cited by 3
ApoE-T807-modified tanshinone IIA liposomes enhance cognitive function in APP/PS1 mice by inhibiting Tau phosphorylation via the PI3K/AKT signaling pathway
Wang, X., Cui, L., Kong, L., Zou, S.-F., & Zhao, X. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107219 · Cited by 3
Comparison of visual and analytic methods of Alzheimer's disease pathologic staging
Lopresti, B. J., Cohen, A. D., DelBene, A., Reese, A. C., Matan, C., Gogola, A., Chiang, M., Snitz, B. E., Laymon, C. M., Berman, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70520 · Cited by 4
Molecular Insights into the Effect of S262 Phosphorylation on the Binding of Tau256–267 to Microtubule and Its Self-Aggregation
Xu, Z., Tang, J., Yi, W., Guan, L., Qi, B., & Zou, Y. F. (2025) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5c03383 · Cited by 3
Biomolecular phase separation of microtubule-associated protein tau and its role in the genesis of brain disorders
Bhandari, A. K., Dhami, A. S., Hemanthlumar, R. T., Mishra, N., Joslyn, B., Roy, S., Srinivasan, J., Prajapati, K. P., Kar, K., & Anand, B. G. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102879 · Cited by 4
Fingolimod treatment exacerbates tau phosphorylation and neurodegeneration in a mouse model of tauopathy with accumulated brain CD8+ T cells
Uenishi, R., Kawata, R., Manabe, T., Takeo, T., Hijioka, M., & Saito, T. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf330 · Cited by 4
The role of neutrophils, red blood cells, and platelets in the pathology of Alzheimer’s disease
Xu, Y., Li, X., Zhao, Q., & Xu, X. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2575110 · Cited by 3
Transferrin-Functionalized Liposomes Enhance MAPT-ASO Transport Across a 3D Blood–Brain Barrier Microvascular Network Model
Konig, S., Shen, X., Mantovani, G., Winkler, G. S., Zhu, Z., & Moeendarbary, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311347 · Cited by 3
Tau clearance reverses touch neuron dysfunction in both young and aged C. elegans
Carroll, T., Johnson, G. V. W., & Nehrke, K. W. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251392935 · Cited by 3
The metabolic-epigenetic interface: lysine succinylation orchestrates bidirectional crosstalk in neurodegenerative disorders
Fanglei, C. H. A. I., Liu, C., Liu, Y., & Zou, W. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1678595 · Cited by 3
In Vitro and In Vivo Evaluation of Small-Molecule Disassemblers of Pathological Tau Fibrils
Pan, H., Cheng, X., Zhang, J., Hou, K., Murray, K. A., Manglani, K., Zhu, C., Hsu, H., Mekkittikul, M., Halladay, T., et al. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00940 · Cited by 3
Neuromechanobiology: Bridging Mechanobiology and Neuroscience Through Evidence and Open Questions
Zimkowska, K., Riu-Villanueva, M., & del Rı́o, J. A. (2026) · Cells · doi:10.3390/cells15020178 · Cited by 3
Salivary total tau: a clinically practical measure of tau neuropathology in Alzheimer’s disease
Bamford, A. R., Logan, C., Do, Q. B., Nguyen, K., McMillan, L. C., Yassa, M. A., Shankle, W. R., & Thomas, E. A. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13651-1 · Cited by 3
Dietary Bioactives in Alzheimer’s Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies
Kumari, A., & Zeng, X.-A. (2026) · Nutrients · doi:10.3390/nu18060907 · Cited by 4
Bridging the gaps in alzheimer’s disease: a comprehensive review of current and emerging therapies
Mostafa, R. E., & Asaad, G. F. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02151-3 · Cited by 5
Ferroptosis in Neuropsychiatric and Neurodegenerative Disorders: Shared Mechanisms and Disease-Specific Signatures
Liu, M., Zeng, C., & Si, Z. (2026) · Pharmaceuticals · doi:10.3390/ph19040629 · Cited by 3
Icariin promotes lysosomal degradation of amyloid-β precursor protein via enhanced endosome-lysosome trafficking to reduce amyloid-β accumulation and improve cognitive function in Alzheimer’s disease models
Lin, C., Xu, Z., Yan, J., Liu, B., & Li, F. (2026) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2026.111906 · Cited by 3
A new era in neuropharmacology: assessing the efficacy and safety of novel anti-amyloid and non-amyloid drug targets for Alzheimer's disease
Hafez, M. M., Abbas, H. A., Shoman, N. A., Soubh, A. A., Aly, O., Sallam, M. F., Seliem, M. A., & Malaak, F. A. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13829-7 · Cited by 3
From Molecular Networks to Medicines: Targeting Complexity in Alzheimer’s Disease (AD) Therapy
Kumar, D. R. P., Patel, S., Mishra, P. S., Srivastava, S., Sridhar, S. B., Shareef, J., Sahu, R., Tariq, M., Uddin, J., & Muhsinah, A. B. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05909-6 · Cited by 3
Sercocephalous latifolius fruit attenuates aluminum chloride-induced oxidative stress and neurotoxicity in Drosophila melanogaster via Drn1 regulation of the IMD signaling pathway
Saliu, J. A., Olajuyin, A. M., & Monday, O. O. (2024) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2024.100437 · Cited by 3
Modulation of Amyloid and Tau Aggregation to Alleviate Cognitive Impairment in a Transgenic Mouse Model of Alzheimer’s Disease
Park, S., Shin, J., Kim, K., Kim, D., Lee, W. S., Lee, J., Cho, I., Park, I. W., Yoon, S., Lee, S., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00006 · Cited by 3
Enzymes and Alzheimer's Disease: Pioneering Drug Development Strategies
Godwa, T., Dubey, S., & Tiwari, P. K. (2025) · Current Psychopharmacologye · doi:10.2174/0122115560340307250106065419 · Cited by 3
2-(Phenylamino)-7,8-dihydroquinazolin-5(6H)-one, a promising scaffold for MAO-B inhibitors with potential GSK3β targeting
Paolo, M. L. D., Salerno, S., Nordio, G., Piazzola, F., Sarno, S., Sarno, G., Natale, B., Poggetti, V., Borreca, A., Baglini, E., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117580 · Cited by 4
Fyn-dependent Tau microcluster formation seeds and boosts extensive Tau pathology
Li, Y., Qi, W., Chen, L., Chu, F., Jiang, W., Xu, Z., Luo, Y., Hu, X., Götz, J., & Li, C. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02887-2 · Cited by 3
Bridging prion biology and Alzheimer’s disease: from pathogenic seeds to precision therapeutics
Wang, W., Feng, Z., Shu, L., Hu, Y., Chen, Y., Zhang, B., & Huang, H. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1660151 · Cited by 3
Neurotrophic factor-α1/carboxypeptidase E regulates critical protein networks to rescue neurodegeneration, defective synaptogenesis and impaired autophagy in Alzheimer’s disease mice
Xiao, L., Sharma, P., Yang, X., Abebe, D. T., & Loh, Y. P. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00520-6 · Cited by 3
Generation of Alzheimer’s Disease Model Derived from Induced Pluripotent Stem Cells with APP Gene Mutation
Kim, Y., Yun, B., Ye, B. S., & Kim, B. Y. (2024) · Biomedicines · doi:10.3390/biomedicines12061193 · Cited by 3
Virtual screening and molecular dynamics of anti-Alzheimer compounds from Cardiospermum halicacabum via GC-MS
Kaviyarasu, S., Padmanaban, N., Khute, S., Zengin, G., & Subash, P. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1586728 · Cited by 3
Osthole's capacity to prevent tau aggregation, a key protein in tauopathy and Alzheimer's disease
Liu, W., Xu, H., Wang, C., Geng, G., Yang, Y., & Chen, G. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143235 · Cited by 3
Single-Domain Antibody-Based Protein Degrader for SynucleinopathiesPreprint
Jiang, Y., Lin, Y., Tetlow, A. M., Pan, R., Ji, C., Kong, X., Congdon, E. E., & Sigurdsson, E. M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.11.584473 · Cited by 3
Therapeutic Potential of Traditional Oriental Medicines in Targeting Tau Pathology: Insights from Cell-free and Cell-based Screening
Park, H. H., Kim, B., Leem, S. H., Park, Y. H., Chung, H., Yoo, D., Park, I., Nam, Y., Kim, S., Shin, S. J., et al. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673295901240311072440 · Cited by 2
Mechanical stimulation prevents impairment of axon growth and overcompensates microtubule destabilization in cellular models of Alzheimer’s disease and related Tau pathologies
Galeotti, A. A., Santucci, L., Klimek, J., Kabbani, M. A. A., Zempel, H., & Raffa, V. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1519628 · Cited by 2
Simultaneous profiling of cholinesterases and NAD(P)H in murine hippocampus via a dual-responsive indicator to investigate cholinergic impairment in Alzheimer's disease
Jiang, B., Guan, J., Lv, Y., Yang, C., Yang, M., Shen, X., Xu, B., Wang, Q., Qin, Y., & Wu, L. J. (2025) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2025.138511 · Cited by 2
Advancing nanotheranostics for neuro-immunological disorders: current status and future prospects
Rai, S., Nair, A., Saleem, Z., Ray, S. K., Kanwar, J. R., & Mukherjee, S. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.08.051 · Cited by 2
Precision therapeutics for Alzheimer’s disease
Priyanka, S., Manjari, T., Hemalatha, S., Ambika, S., Yilmaz, B. N., Aktürk, B., Arısan, E. D., Kumari, A., & Manojkumar, Y. (2025) · Progress in brain research · doi:10.1016/bs.pbr.2025.08.011 · Cited by 2
Active immunization: A novel therapeutic strategy for treating Alzheimer's disease
Mazahir, F. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178288 · Cited by 3
rTg4510 Tauopathy Mice Exhibit Non-Spatial Memory Deficits Prevented by Doxycycline Treatment
Kishimoto, Y., Kubota, T., Nakashima, K., & Kirino, Y. (2025) · Brain Sciences · doi:10.3390/brainsci15111183 · Cited by 2
Alzheimer Syndrome or Age-Related Dementia—History, Therapy and Prevention
Bermejo‐Pareja, F., & del Ser, T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217752 · Cited by 2
A recurrent ACAA2 variant causes a dominant syndrome of lipodystrophy, lipomatosis, infantile steatohepatitis, and hypoglycemia
Simha, V., LoPiccolo, M. K., Platt, A., Brown, R. J., Johnson, X., Carere, D. A., Donnelly, C. M., Snyder, M. T., Xing, C., Mathews, T. P., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci198888 · Cited by 2
Large-scale seroepidemiology uncovers nephro-urological pathologies in people with tau autoimmunity
Magalhães, A. D., Emmenegger, M., De Cecco, E., Carta, M., Frontzek, K., Chincisan, A., Guo, J., Hornemann, S., & Aguzzi, A. (2025) · PLOS Biology · doi:10.1371/journal.pbio.3003488 · Cited by 2
Proteins Associated with Cognition in Amyloid-beta Positive Elders Based on Cerebrospinal Fluid Proteomics
Liu, M., Hu, H., Fu, Y., Chi, H., Huang, L.-Y., Tan, L., & Hu, H. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05442-y · Cited by 2
Cumulative blood pressure and risk of dementia and cognitive decline: a systematic review and meta-analysis
Wang, R., Gao, Y., Ee, N., Akinyede, F., Xu, X., Chen, L., Xiong, S., Chen, X., Anderson, C. S., Harris, K., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100500 · Cited by 2
Aerobic exercise facilitates p300 nuclear translocation via ADRB2-AMPKα signaling, leading to enhanced histone acetylation and mitigation of cognitive decline in APP/PS1 mice
Chai, G.-S., Gao, T.-L., Bi, S.-G., Mao, Y.-M., Yang, L., Wang, F.-Z., Chen, J., Wu, J.-J., Gong, J., Geng, S., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01983-z · Cited by 3
Neuroinflammation as a driver of Down syndrome-associated Alzheimer’s disease
Qu, H., Snorradóttir, Á. Ó., Gutierrez-Uzquiza, A., Kao, C., March, M., & Hakonarson, H. H. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106513 · Cited by 2
Modulating LRP1 Pathways in Alzheimer’s Disease: Mechanistic Insights and Emerging Therapies
Mushtaq, T., Hameed, H., Khan, M. A., Tariq, U., Hameed, A., & Zaman, M. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05775-2 · Cited by 2

Authors: Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M.
Affiliations: New York University (US)
NYU Langone Health (US)
Corresponding author: Sigurdsson, Einar M.
ORCID: Congdon, Erin E.
Ji, Changyi
Tetlow, Amber M.
Jiang, Yixiang
Sigurdsson, Einar M.
Venue: Nature Reviews Neurology
Publisher: Springer Science and Business Media LLC
Published: 2023-10-24
Volume: 19
Issue: 12
Pages: 715-736
ISSN: 1759-4758 (ISSN-L)
1759-4766
DOI: 10.1038/s41582-023-00883-2
PMC: PMC10965012
OpenAlex: W4387904363
Cited by: 371
References: 380
Citations by year: 2026: 125 · 2025: 170 · 2024: 74 · 2023: 1
FWCI: 13.17
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Reviews Neurology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Alzheimer's Association (AG032611, AARF-22-924783)
National Institutes of Health (NS120488)
National Institute on Aging (R21AG069475, R01AG032611, T32AG052909)
National Institute of Neurological Disorders and Stroke (RF1NS120488, R01NS120488, R01NS077239)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: Alzheimer's disease, tau protein, tau immunotherapy, tau aggregation, microtubule stabilization, post-translational modification, amyloid plaques, neurofibrillary tangles, clinical trials, drug candidates
MeSH terms: Aged, Alzheimer Disease, Humans, Immunotherapy, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tau-targeting therapies for Alzheimer disease: current status and future directions

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks